---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005802"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:42:39.859873+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasmus MC Safety Committee approves Phase 2 study of Ampligen + Imfinzi for late-stage pancreatic cancer

## Summary
- Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
- Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
- CEO Tom Equels and Prof. van Eijck discussed milestone in Virtual Investor segment.
- Study is investigator-initiated, single-center at Erasmus MC in the Netherlands.

## SEC filing metadata
- accession: 0001493152-25-005802
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315225005802/0001493152-25-005802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315225005802/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005802
- JSON: https://secwatch.observer/filing/0001493152-25-005802.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.